Close Menu

NEW YORK – Roche announced Thursday its Cobas EGFR Mutation Test v2 received approval from the US Food and Drug Administration of expanded claims as a companion diagnostic for non-small cell lung cancer therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.